Drew McElligott's practice focuses on patent and trademark litigation, representing leading companies in the pharmaceutical and medical device sectors, as well as consumer products manufacturers.
Drew has had significant experience at all stages of federal district court litigation and has developed experience in complex case management, coordination of global discovery efforts, Markman strategy and briefing, and the selection and preparation of expert witnesses. Drew has also gained extensive experience briefing and arguing inter partes reviews, before the United States Patent and Trademark Office.
He has also co-authored multiple scientific articles in medical and cardiology publications, and published article on licensing-related issues for the International Trade Commission Trial Lawyers’ Association.
Before practicing law, Drew worked for four years at the Loyola University Cardiovascular Institute conducting scientific research and gaining expertise in a variety surgical and diagnostic procedures and techniques. Drew now applies the strong analytical and creative problem-solving skills that he honed in the laboratory to helping his clients protect their innovations and achieve their long-term goals.
Recognition
- The Best Lawyers: Ones to Watch–Intellectual Property Law, 2021
- Hon. Howard T. Markey Distinguished Scholar, 2011–2014
- Lead Articles Editor, The John Marshall Review of Intellectual Property Law
- Board Member, Trial Advocacy and Dispute Resolution Honors Council
Affiliations
- The Copyright Society of the USA
- Phi Alpha Delta Legal Fraternity
- The Order of John Marshall
Admissions
Admitted to practice: Illinois, U.S. Patent and Trademark Office (USPTO)
Publications
-
"SCOTUS' 131-year itch: Georgia v Public.Resource.Org, Inc," Intellectual Property Magazine
(February 2020).
Author: Andrew McElligott
-
A Higher Bar for Establishing a Licensing-Based Domestic Industry, 37 ITC TRIAL LAW. ASS'N, 337 REP.: The Paul J. Luckern Summer Associate Edition 59 (2013).
(2013).
Author: Andrew McElligott
-
Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction, co-author, 52 J. OF MOLECULAR AND CELLULAR CARDIOLOGY 154 (2012).
(2012).
Author: Andrew McElligott
-
Novel approach to admittance to volume conversion for ventricular volume measurement, co-author, CONF PROC IEEE ENG MED BIOL SOC. (2011); 2011:2514-7.
(2011).
Author: Andrew McElligott
-
Connective Tissue Growth Factor Gene Expression in the Failing Human Heart, co-author, 29 THE J. OF HEART AND LUNG TRANSPLANTATION 61 (Supp. 2010).
(2010).
Author: Andrew McElligott
-
Deiodinase Expression in a Rodent Model of Myocardial Infarction, co-author, FASEB J. 23:626.2 (2009).
(2009).
Author: Andrew McElligott
Client Alerts & Newsletters
-
"Twitter, Inc. v. Vidstream LLC, No. 19-1708 (Fed. Cir. 2020),"
IP Insights
(September 11, 2020).
Contacts: David P. Lindner, Andrew McElligott
-
"SCOTUS Agrees To Address Edicts Doctrine For First Time In 130 Years,"
IP Insights
(June 26, 2019).
Contacts: William H. Frankel, Andrew McElligott
-
"Supreme Court Holds That Copyright Owners Must Wait for Registration Before Filing Suit,"
IP Insights
(March 5, 2019).
Contacts: William H. Frankel, Andrew McElligott
-
"Only a Patent Owner's Action Triggers ยง 315(b)'s Time Bar,"
IP Insights
(February 8, 2019).
Contacts: Douglas A. Oguss, Andrew McElligott
Firm News & Announcements